CCTC NATCO Exam 2024( Graded A+)

CCTC NATCO Exam 2024( Graded A+) Lymphocyte Depleting induction agent - ANSWERSAnti-thymocyte globulin 5-6 mg/kg IV in divided doses 1st dose intraoperatively Alemtuzumab (Campath) 30 mgIV x 1 dose Given introperatively Muromonab (OKT3)anti CD3 monoclonal 5 mg IV daily for 10 days Lymphocyte Non-depleting induction agent reaction - ANSWERSIL2 Simulect (basiliximab) Binds to CD25 on active T lymphocytes Inhibits IL2 mediated T-lymphocytes Kidney/liver top induction Dose 20 mg IV c 2 doses 1st dose Ontario 2 bd dose given on POD4 Leflunomide (Arava) - ANSWERSLymphocyte proliferation 40 mg PO daily May be totrated from 20-100 mg day until BK virus serum PCR undetectable MELD score - ANSWERSNa Serum bilirubin Creatinine INR ProstaglandinE-1 - ANSWERSFree radical inhibition Inhibition of platelet / WBC aggregation Improvement of hepatic micro circulation Inhibitionnof cytokines release Titrationnof BP Reduce post ischemic repercussion injury skin cancer risk factors - ANSWERSCertain meds Variconazole Aziathroprine Ruxolitinib(jakafi) Increase in immunosuppression for organ rejection Age